STOCK TITAN
  1. Home
  2. Sec-filings
  3. ARWR
  4. [144] ARROWHEAD PHARMACEUTICALS, INC. SEC Filing

Arrowhead (NASDAQ: ARWR) director to sell 11,600 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) director Michael Perry has filed a notice of proposed sale of common stock under Rule 144. He plans to sell up to 11,600 shares of Arrowhead common stock through Merrill Lynch on NASDAQ, with an estimated aggregate market value of $1,012,171.97. The shares were acquired from the issuer as compensation on several dates in 2021, 2022, and 2025. Arrowhead had 141,254,467 shares outstanding of common stock; this is a baseline figure, not the amount being offered.

Positive

  • None.

Negative

  • None.
Shares proposed to be sold 11,600 shares Number of Arrowhead common shares listed for potential sale under Rule 144
Aggregate market value of shares $1,012,171.97 Estimated aggregate market value of the 11,600 shares proposed for sale
Shares outstanding 141,254,467 shares Arrowhead Pharmaceuticals common shares outstanding as referenced in the notice
Compensation shares 2025 grant 600 shares Common shares acquired as compensation on 12/18/2025
Compensation shares 2022 grant 9,000 shares Common shares acquired as compensation on 01/01/2022
Compensation shares 2021 grant 2,000 shares Common shares acquired as compensation on 01/01/2021
Proposed sale date 08/18/2026 Approximate date of sale for the Rule 144 transaction
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
aggregate market value financial
"11600 | 1012171.97 | 141254467 | 08/18/2026"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.
compensation financial
"Common | 12/18/2025 | Compensation | Issuer"

FAQ

What does the Form 144 filing disclose for ARWR?
The filing discloses that director Michael Perry plans to sell up to 11,600 ARWR common shares under Rule 144, with an estimated aggregate market value of $1,012,171.97, through Merrill Lynch on NASDAQ.

How many Arrowhead Pharmaceuticals (ARWR) shares are proposed to be sold?
Michael Perry has noticed a proposed sale of 11,600 shares of Arrowhead Pharmaceuticals common stock. These shares correspond to awards acquired as compensation on multiple grant dates in 2021, 2022, and 2025.

What is the estimated value of the ARWR shares Michael Perry plans to sell?
The proposed sale covers shares with an aggregate market value of $1,012,171.97. This estimate relates specifically to the 11,600 shares identified for potential sale under Rule 144 through Merrill Lynch.

How were the ARWR shares that may be sold by Michael Perry acquired?
The shares were acquired from Arrowhead Pharmaceuticals as compensation. They are broken down as 600 shares (12/18/2025), 9,000 shares (01/01/2022), and 2,000 shares (01/01/2021), totaling 11,600 shares.

How does the proposed sale size compare to Arrowhead Pharmaceuticals’ (ARWR) shares outstanding?
Arrowhead Pharmaceuticals had 141,254,467 shares outstanding of common stock. The proposed 11,600-share sale by Michael Perry relates only to his holdings and does not represent the total shares outstanding.

Who is the broker for the proposed ARWR stock sale under Form 144?
The proposed sale of 11,600 ARWR shares is listed with Merrill Lynch, located at 75 Rockefeller Plaza, New York. The shares are intended to be sold on NASDAQ under Rule 144, subject to applicable conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR